Why the study?
Does the uncaging coronary DynamX bioadaptor system provide safety, efficacy, and positive vessel remodeling at 12 months?
Does the uncaging coronary DynamX bioadaptor system provide safety, efficacy, and positive vessel remodeling at 12 months?
The DynamX bioadaptor demonstrates safety and positive vessel remodeling at one year, supporting its potential as a novel coronary intervention device, though randomized trials are needed.
Supports bioadaptor evaluation in CAD; hypothesis-generating and should not yet change practice pending RCTs.
The DynamX bioadaptor showed drug-eluting stent-like acute performance and safety and efficacy up to one year. Positive remodelling with an increase of vessel and device area while maintaining the mean lumen area was demonstrated. Long-term follow-up and randomised trials are required to assess the benefit of this device on events beyond one year.
No takes yet. Share an insight, caveat, or question.
Verheye et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: